Form 8-K ILLUMINA, INC. For: May 06
- Nasdaq closes lower as chipmaker Micron's warning renews tech rout
- Citi’s Top Equity Strategist Warns Analysts are Too Bullish on Stocks
- Bank of America Clients Continue to Buy the Rally, New Data Shows
- Novavax (NVAX) Crashes 30% After a Deep Guidance Cut, Analyst 'Frustrated'
- 'Hard to Say' Whether Current Crypto Bear Market is Over - Morgan Stanley
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 6, 2022
(Exact name of registrant as specified in its charter)
(Commission File Number)
|(State or other jurisdiction of incorporation)||(I.R.S. Employer Identification No.)|
(Address of principal executive offices) (Zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. o
Item 8.01 Other Events.
On May 6, 2022, a jury in the U.S. District Court for the District of Delaware rendered a verdict that Illumina, Inc. (the “Company”) willfully infringed U.S. Patent Nos. 9,222,132 and 10,662,473 owned by Complete Genomics, Inc. (“CGI”), and awarded approximately $334 million to CGI in past damages. The jury also invalidated three patents owned by the Company, namely, U.S. Patent Nos. 9,217,178; 9,303,290; and 9,970,055. The Company disagrees with the jury’s verdict and intends to vigorously defend the action, including filing all appropriate appeals. If our appeals are unsuccessful, we could be required to pay interest on the judgment and an ongoing royalty at a rate to be determined by the court until the patents expire in January 2029. In addition, although CGI may seek an injunction, we do not believe there is a reasonable basis for the court to grant one.
Item 9.01 Financial Statements and Exhibits.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
May 6, 2022
/s/ CHARLES E. DADSWELL
|Charles E. Dadswell|
|General Counsel and Secretary|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics
- Verizon Business Selected to Transform Astellas Pharma’s Global Network Infrastructure
- MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meetin
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!